
New hope as experimental Alzheimer's drug appears to slow worsening of the disease by a third
People in the early stages of Alzheimer’s who received infusions of donanemab in the 18-month trial showed 35 per cent less decline.
Read full articlePeople in the early stages of Alzheimer’s who received infusions of donanemab in the 18-month trial showed 35 per cent less decline.
Read full article